FATE
Price
$1.17
Change
-$0.08 (-6.40%)
Updated
Apr 29, 04:42 PM (EDT)
Capitalization
143.25M
One day until earnings call
NTLA
Price
$8.20
Change
-$0.28 (-3.30%)
Updated
Apr 29, 04:59 PM (EDT)
Capitalization
877.83M
2 days until earnings call
Ad is loading...

FATE vs NTLA

Header iconFATE vs NTLA Comparison
Open Charts FATE vs NTLABanner chart's image
Fate Therapeutics
Price$1.17
Change-$0.08 (-6.40%)
Volume$587
Capitalization143.25M
Intellia Therapeutics
Price$8.20
Change-$0.28 (-3.30%)
Volume$45.54K
Capitalization877.83M
FATE vs NTLA Comparison Chart
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. NTLA commentary
Apr 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and NTLA is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 29, 2025
Stock price -- (FATE: $1.25 vs. NTLA: $8.48)
Brand notoriety: FATE and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 48% vs. NTLA: 91%
Market capitalization -- FATE: $143.25M vs. NTLA: $877.83M
FATE [@Biotechnology] is valued at $143.25M. NTLA’s [@Biotechnology] market capitalization is $877.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $279.46B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 5 TA indicator(s) are bullish while NTLA’s TA Score has 4 bullish TA indicator(s).

  • FATE’s TA Score: 5 bullish, 5 bearish.
  • NTLA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both FATE and NTLA are a good buy in the short-term.

Price Growth

FATE (@Biotechnology) experienced а 0.00% price change this week, while NTLA (@Biotechnology) price change was +7.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.09%. For the same industry, the average monthly price growth was -2.03%, and the average quarterly price growth was -10.94%.

Reported Earning Dates

FATE is expected to report earnings on Jul 30, 2025.

NTLA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($878M) has a higher market cap than FATE($143M). FATE YTD gains are higher at: -24.242 vs. NTLA (-27.273). FATE has higher annual earnings (EBITDA): -176.58M vs. NTLA (-523.98M). NTLA has more cash in the bank: 602M vs. FATE (279M). FATE has less debt than NTLA: FATE (85.3M) vs NTLA (210M). NTLA has higher revenues than FATE: NTLA (57.9M) vs FATE (13.6M).
FATENTLAFATE / NTLA
Capitalization143M878M16%
EBITDA-176.58M-523.98M34%
Gain YTD-24.242-27.27389%
P/E RatioN/AN/A-
Revenue13.6M57.9M23%
Total Cash279M602M46%
Total Debt85.3M210M41%
FUNDAMENTALS RATINGS
FATE vs NTLA: Fundamental Ratings
FATE
NTLA
OUTLOOK RATING
1..100
286
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
4886
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (16) in the Biotechnology industry is in the same range as NTLA (26). This means that FATE’s stock grew similarly to NTLA’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NTLA (100). This means that FATE’s stock grew similarly to NTLA’s over the last 12 months.

FATE's SMR Rating (97) in the Biotechnology industry is in the same range as NTLA (97). This means that FATE’s stock grew similarly to NTLA’s over the last 12 months.

FATE's Price Growth Rating (48) in the Biotechnology industry is somewhat better than the same rating for NTLA (86). This means that FATE’s stock grew somewhat faster than NTLA’s over the last 12 months.

FATE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NTLA (100). This means that FATE’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FATENTLA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 8 days ago
85%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 14 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X94978.7500001223.914100
+1.31%
Bitcoin cryptocurrency
GME27.590.13
+0.47%
GameStop Corp
AAPL210.140.86
+0.41%
Apple
TSLA285.880.93
+0.33%
Tesla
SPY550.850.21
+0.04%
SPDR® S&P 500® ETF

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-2.34%
ALLO - FATE
56%
Loosely correlated
+1.29%
NTLA - FATE
53%
Loosely correlated
+2.05%
CRBU - FATE
51%
Loosely correlated
-0.30%
CRSP - FATE
51%
Loosely correlated
-1.02%
CCCC - FATE
49%
Loosely correlated
+5.19%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been loosely correlated with CRSP. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if NTLA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+2.05%
CRSP - NTLA
66%
Loosely correlated
-1.02%
BEAM - NTLA
64%
Loosely correlated
+1.43%
RXRX - NTLA
60%
Loosely correlated
+1.92%
RCKT - NTLA
59%
Loosely correlated
-0.97%
ABCL - NTLA
58%
Loosely correlated
+0.78%
More